My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
12-20-21-SR
ArdenHills
>
Administration
>
City Council
>
City Council Packets
>
2020-2029
>
2021
>
12-20-21-SR
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
12/16/2021 1:10:50 PM
Creation date
12/16/2021 1:10:23 PM
Metadata
Fields
Template:
General
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
53
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />Minnesota Opioid State-Subdivision Agreement Overview <br />What It Is <br /> <br />The Minnesota Memorandum of Agreement (MN MOA) governs how Minnesota will distribute <br />settlement funds from two national settlements with opioid distributors McKesson, Cardinal <br />Health, and AmerisourceBergen and opioid manufacturer Johnson & Johnson. These settlements <br />could bring more than $296 million to Minnesota over an 18-year period to support state and local <br />efforts to fight the opioid epidemic.1 <br /> <br />How It Works <br /> <br />Enables Minnesota to maximize resources to fight the epidemic. For Minnesota to receive the <br />maximum payout under the two national settlements, cities and counties must join the state and <br />sign on to the MN MOA and the settlement agreements. To maximize resources flowing to <br />communities on the front lines of the epidemic, the MN MOA directs settlement funds as follows: <br /> <br /> 75 percent to local governments, including all counties and 33 cities. <br /> 25 percent to the state, to be overseen and distributed by the Opioid Epidemic Response <br />Advisory Council. <br /> <br />Dedicates funds to addressing the opioid epidemic. The Attorney General’s Office convened <br />an expert panel of local, state, and community providers with experience and expertise in public <br />health and delivery of health care services to determine the best and most effective use of the <br />settlement funds. The panel selected a comprehensive list of future opioid abatement and <br />remediation programs to which these settlement funds must be dedicated. <br /> <br />Why It Matters <br /> <br />Personal Cost. More than 5,400 Minnesotans have died of opioid overdoses since 2000. The <br />epidemic has torn families apart and ravaged communities, particularly American Indian <br />populations and communities of color. Individuals, families, and communities continue to suffer, <br />as the COVID-19 pandemic has caused a surge in both fatal and nonfatal overdose deaths. <br /> <br />Accountability. Opioid manufacturers and distributors created and fueled the opioid epidemic <br />with irresponsible and misleading marketing and inadequate monitoring of these dangerous <br />products. In addition to potentially over $296 million to fight the epidemic, settlements with the <br />three largest drug distributors in the country, as well as one of the largest manufacturers, will shine <br />a light on these companies’ conduct and help make sure nothing like this ever happens again. <br /> <br />1 The MN MOA also governs how opioid abatement funds from the bankruptcy resolutions with <br />Purdue Pharma and Mallinckrodt are distributed within Minnesota. The $296 million figure does <br />not include payments from the Purdue Pharma and Mallinckrodt bankruptcies, which are not yet <br />finalized.
The URL can be used to link to this page
Your browser does not support the video tag.